Clinical trial risk in castration-resistant prostate cancer: immunotherapies show promise-Reference-Cited by-同舟云学术

Clinical trial risk in castration-resistant prostate cancer: immunotherapies show promise

Published:2013-12-02 Issue:5b Volume:113 Page:E82-E89
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Tenuta Alessandro¹,Klotz Laurence²,Parker Jayson L.³

Affiliation:

1. Department of Management; University of Toronto at Mississauga; Toronto ON Canada

2. Sunnybrook Hospital; Toronto ON Canada

3. Department of Biology; University of Toronto at Mississauga; Toronto ON Canada

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.12309/fullpdf

Reference22 articles.

1. Significance of the human genome sequence to drug discovery;Grenet;The Pharmacogenomics Journal,2001

2. Lessons from 60 years of pharmaceutical innovation;Munos;Nat Rev Drug Discov,2009

3. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade 2000-2009;Kaitin;Clin Pharmacol Ther,2011

4. Harris G Federal research centre will help develop medicines The New York Times: Money and Policy 2011 http://www.nytimes.com/2011/01/23/health/policy/23drug.html

5. The economics of drug development: a grim reality and role of clinical pharmacology;Honig;Clin Pharmacol Ther,2010

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does biomarker use in oncology improve clinical trial failure risk? A large‐scale analysis;Cancer Medicine;2021-02-23

2. Clinical trial risk in leukemia: Biomarkers and trial design;Hematological Oncology;2020-10-28

3. A Risk-Based Paradigm of Biomarkers in Clinical Trials;Companion and Complementary Diagnostics;2019

4. Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action;Canadian Journal of Gastroenterology and Hepatology;2016

5. Reducing clinical trial risk in multiple sclerosis;Multiple Sclerosis and Related Disorders;2016-01